PLYMOUTH, Mich.--(BUSINESS WIRE)--Materialise NV (Nasdaq:MTLS), a leading provider of 3D printing services and software solutions, and Siemens Healthineers, a leading medical technology company announced today that they are joining forces to bring Materialise Mimics inPrint software to hospitals around the world. 3D printing technology is growing rapidly in the medical field, and soon it will be even more mainstream as 3D printing software becomes more accessible in hospitals. The partnership, announced at the 2017 Radiological Society of North America (RSNA) Annual Meeting, makes Materialise Mimics inPrint software, a dedicated solution for printing anatomical models in hospitals, available to radiologists through the Siemens Healthineers syngo.via open app platform.
Adopting virtual 3D anatomical models facilitates surgical planning and collaboration between radiologists and surgical teams. 3D-printed anatomical models improve patient communication, training and education surrounding anatomically complex pathologies.
“We believe 3D printing is going to revolutionize the medical industry and we are always looking for ways to improve accessibility of our 3D printing software to more patients and hospitals,” said Brigitte de Vet, Vice President of Medical at Materialise. “By partnering with other global healthcare leaders like Siemens Healthineers, we can do just that, and more importantly, we can further contribute to a better and healthier world.”
By integrating the software into syngo.via, Mimics inPrint is directly incorporated into the standard hospital workflow. This allows for safe and easy access to in-house and Materialise-powered 3D printing services. This will facilitate the integration of 3D printing within clinical environments, contributing to higher quality, cost-efficient care for patients and hospitals. Each patient will now have access to more personalized care through Materialise’s patient-specific anatomical models.
“By incorporating 3D technology into syngo.via, we jointly support the entire workflow from patient diagnosis to therapy planning,” said Valentin Ziebandt, Head of Marketing at the Syngo Business Line at Siemens Healthineers. “This is a cost-effective way to increase the clinical capabilities of syngo.via and an important step towards achieving personalized care and precision medicine.”
For more information on this partnership and the Materialise Mimics inPrint software visit www.materialise.com/en/medical/3d-printing-introduced-into-your-workflow or stop by the Materialise booth, #7932 in the North - Hall B, during the 2017 RSNA Annual Meeting at McCormick Place in Chicago from November 26 – December 1.
About Materialise
Materialise incorporates 27 years of 3D
printing experience into a range of software solutions and 3D printing
services, which together form the backbone of the 3D printing industry.
Materialise’s open and flexible solutions enable players in a wide
variety of industries, including healthcare, automotive, aerospace, art
and design, and consumer goods, to build innovative 3D printing
applications that aim to make the world a better and healthier place.
Headquartered in Belgium, with branches worldwide, Materialise combines
the largest group of software developers in the industry with one of the
largest 3D printing facilities in the world. For additional information,
please visit: www.materialise.com.
About Materialise’s Medical Division
Materialise Medical,
which has pioneered many of the leading medical applications of 3D
printing, enables researchers, engineers and clinicians to revolutionize
innovative patient-specific treatment. Materialise Medical’s open and
flexible platform of software and services, Materialise Mimics, form the
foundation of certified Medical 3D Printing, in clinical as well as
research environments, offering virtual planning software tools,
3D-printed anatomical models, and patient-specific surgical guides and
implants. For additional information, please visit:
http://hospital.materialise.com/
Cautionary Statement on Forward-Looking Statements
Some of
the statements in this press release are "forward-looking" and are made
pursuant to the safe harbor provision of the Private Securities
Litigation Reform Act of 1995. These forward-looking statements include
statements relating to, among other things, our planned
commercialization efforts and regulatory approvals of our technologies
as well as the success thereof and our research and development
projects. These forward-looking statements are based upon the
expectations of management under current assumptions at the time of this
press release. We caution you that forward-looking statements are not
guarantees of future performance and involve known and unknown risks,
uncertainties and other factors that are in some cases beyond our
control that may cause our actual results to differ materially from our
expectations. We are providing this information as of the date of this
press release and do not undertake any obligation to update any
forward-looking statements contained in this presentation as a result of
new information, future events or otherwise, unless we have obligations
under the federal securities laws to update and disclose material
developments related to previously disclosed information.
